Table of Content

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY DATA 20
2.1.1.1 Key Data from Secondary Sources 20
2.1.2 PRIMARY DATA 22
2.1.2.1 Key Data from Primary Sources 23
2.1.2.2 Key Industry Insights 24
2.2 MARKET SIZE ESTIMATION 24
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION 26
2.3 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 32
4.1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OVERVIEW 32
4.2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 33
4.3 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 34
4.4 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: GEOGRAPHIC SNAPSHOT 35

5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 MARKET DYNAMICS 36
5.2.1 DRIVERS 37
5.2.1.1 Increasing prevalence of chronic diseases 37
5.2.1.2 Technological advancements in transdermal drug delivery systems 37
5.2.2 RESTRAINTS 38
5.2.2.1 Drug failure and recalls of transdermal drug delivery systems 38
?
5.2.3 OPPORTUNITIES 38
5.2.3.1 Collaborations between pharmaceutical companies and drug delivery firms 38
5.2.3.2 Self-administration and home care drug delivery systems 39
5.2.4 CHALLENGES 39
5.2.4.1 Technical barriers related to skin irritation and permeability 39

6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 40
6.1 INTRODUCTION 41
6.2 TRANSDERMAL PATCHES 42
6.2.1 DRUG-IN-ADHESIVE PATCHES 42
6.2.2 MATRIX PATCHES 43
6.2.3 RESERVOIR MEMBRANE PATCHES 43
6.2.4 MICRONEEDLE PATCHES 43
6.3 TRANSDERMAL SEMISOLIDS 45
6.3.1 GELS 45
6.3.2 OINTMENTS 45
6.3.3 SPRAYS 46

7 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 47
7.1 INTRODUCTION 48
7.2 PAIN MANAGEMENT 49
7.2.1 PAIN MANAGEMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET 49
7.3 HORMONAL APPLICATIONS 51
7.3.1 TESTOSTERONE REPLACEMENT THERAPY 52
7.3.1.1 Skin irritation, poor absorption of drugs, high costs, and the need for frequent dosing are factors limiting market growth 52
7.3.2 TRANSDERMAL ESTROGEN THERAPY 53
7.3.2.1 Growing use of transdermal contraceptive patches is likely to drive the market for transdermal estrogen therapy 53
7.4 CENTRAL NERVOUS SYSTEM DISORDERS 53
7.4.1 INCREASING INCIDENCE OF PARKINSON’S AND ALZHEIMER’S DISEASE TO DRIVE THE MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS 53
7.5 CARDIOVASCULAR DISEASES 55
7.5.1 AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH 55
7.6 OTHER APPLICATIONS 57
7.6.1 INCREASING DEMAND FOR ADVANCED TRANSDERMAL MICRONEEDLE PATCHES FOR DIABETES MANAGEMENT?A KEY MARKET DRIVER 57
?

8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 59
8.1 INTRODUCTION 60
8.2 HOME CARE SETTINGS 61
8.3 HOSPITALS & CLINICS 62

9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION 64
9.1 INTRODUCTION 65
9.2 NORTH AMERICA 67
9.2.1 US 70
9.2.1.1 Rising prevalence of targeted disease and development of technologically advanced transdermal drug delivery systems?key factors driving market growth 70
9.2.2 CANADA 72
9.2.2.1 Rising prevalence of chronic diseases and funding for the development of transdermal drug delivery systems to drive market growth 72
9.3 EUROPE 74
9.3.1 GERMANY 77
9.3.1.1 Growing focus of pharmaceutical companies in Germany on the development of transdermal products to drive market growth 77
9.3.2 UK 79
9.3.2.1 Increasing funding for the R&D of innovative transdermal technologies to drive market growth 79
9.3.3 FRANCE 81
9.3.3.1 Development of transdermal drug delivery systems by local players to support market growth 81
9.3.4 ROE 83
9.4 ASIA PACIFIC 85
9.4.1 JAPAN 88
9.4.1.1 Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth 88
9.4.2 CHINA 91
9.4.2.1 Growing focus of major players in China towards the development of transdermal drug delivery systems to drive market growth 91
9.4.3 INDIA 92
9.4.3.1 Growing awareness among healthcare providers and patients and increasing focus on noninvasive methods of drug delivery to drive market growth 92
9.4.4 ROPAC 94
9.5 ROW 96
?

10 COMPETITIVE LANDSCAPE 99
10.1 OVERVIEW 99
10.2 MARKET SHARE ANALYSIS 100
10.3 MARKET SHARE ANALYSIS, BY APPLICATION 100
10.3.1 PAIN MANAGEMENT 100
10.3.2 HORMONAL APPLICATIONS 101
10.3.3 CENTRAL NERVOUS SYSTEM DISORDERS 101
10.3.4 CARDIOVASCULAR DISEASES 102
10.4 COMPETITIVE SCENARIO 102
10.4.1 PRODUCT LAUNCHES AND APPROVALS 102
10.4.2 EXPANSIONS 103
10.4.3 AGREEMENTS AND COLLABORATIONS 103
10.4.4 ACQUISITIONS 104

11 COMPANY PROFILES 105
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 HISAMITSU PHARMACEUTICAL CO., INC. 105
11.2 MYLAN N.V. 108
11.3 UCB S.A. 110
11.4 NOVARTIS AG 112
11.5 GLAXOSMITHKLINE PLC 114
11.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 116
11.7 JOHNSON & JOHNSON (J&J) 118
11.8 ENDO INTERNATIONAL, INC. 120
11.9 PURDUE PHARMA L.P. 122
11.10 LAVIPHARM 123
11.11 LEAD CHEMICALS CO., INC. 124
11.12 LUYE PHARMA GROUP 125
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX 127
12.1 DISCUSSION GUIDE 127
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 130
12.3 AVAILABLE CUSTOMIZATIONS 132
12.4 RELATED REPORTS 132
12.5 AUTHOR DETAILS 133



List of Figures



FIGURE 1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION 16
FIGURE 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: RESEARCH METHODOLOGY 18
FIGURE 3 RESEARCH DESIGN 19
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 22
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 25
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 25
FIGURE 7 DATA TRIANGULATION METHODOLOGY 26
FIGURE 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 28
FIGURE 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018 29
FIGURE 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018 30
FIGURE 11 GEOGRAPHIC SNAPSHOT: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET 31
FIGURE 12 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS ARE KEY FACTORS DRIVING THE GROWTH OF THE MARKET 32
FIGURE 13 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH AMERICAN MARKET DURING THE FORECAST PERIOD 33
FIGURE 14 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH EUROPEAN MARKET DURING THE FORECAST PERIOD 34
FIGURE 15 JAPAN IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 35
FIGURE 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 36
FIGURE 17 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2018 VS. 2023 (USD MILLION) 41
FIGURE 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 2018 VS. 2023 (USD MILLION) 48
FIGURE 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2018 VS. 2023 (USD MILLION) 60
FIGURE 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2018 VS. 2023 65
FIGURE 21 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT 67
FIGURE 22 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT 75
FIGURE 23 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT 86
FIGURE 24 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT 97
FIGURE 25 KEY DEVELOPMENTS IN THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET (2015–2018) 99
FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2015–2018) 100
FIGURE 27 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2017) 105
FIGURE 28 MYLAN: COMPANY SNAPSHOT (2017) 108
FIGURE 29 UCB: COMPANY SNAPSHOT (2017) 110
FIGURE 30 NOVARTIS: COMPANY SNAPSHOT (2017) 112
FIGURE 31 GSK: COMPANY SNAPSHOT (2017) 114
?
FIGURE 32 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017) 116
FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017) 118
FIGURE 34 ENDO INTERNATIONAL: COMPANY SNAPSHOT (2017) 120
FIGURE 35 LUYE PHARMA: COMPANY SNAPSHOT (2017) 125

 

List of Tables



TABLE 1 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMISOLID FORMULATIONS 41
TABLE 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 42
TABLE 3 TRANSDERMAL PATCHES MARKET, BY TYPE, 2016–2023 (USD MILLION) 44
TABLE 4 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 44
TABLE 5 TRANSDERMAL SEMISOLIDS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 46
TABLE 6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 2016–2023 (USD MILLION) 49
TABLE 7 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR PAIN MANAGEMENT 49
TABLE 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR PAIN MANAGEMENT BY COUNTRY, 2016–2023 (USD MILLION) 50
TABLE 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 51
TABLE 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY TYPE, 2016–2023 (USD MILLION) 52
TABLE 11 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TESTOSTERONE REPLACEMENT THERAPY 52
TABLE 12 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TRANSDERMAL ESTROGEN THERAPY 53
TABLE 13 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CENTRAL NERVOUS SYSTEM DISORDERS 54
TABLE 14 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2016–2023 (USD MILLION) 54
TABLE 15 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CARDIOVASCULAR DISEASES 55
TABLE 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016–2023 (USD MILLION) 56
TABLE 17 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR OTHER APPLICATIONS 57
TABLE 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 58
TABLE 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 60
TABLE 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016–2023 (USD MILLION) 61
TABLE 21 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016–2023 (USD MILLION) 63
TABLE 22 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION 2016–2023 (USD MILLION) 66
TABLE 23 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY COUNTRY, 2016–2023 (USD MILLION) 68
TABLE 24 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION, 2016–2023 (USD MILLION) 68
TABLE 25 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE, 2016–2023 (USD MILLION) 69
TABLE 26 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY END USER, 2016–2023 (USD MILLION) 69
TABLE 27 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 2016–2023 (USD MILLION) 71
TABLE 28 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 71
TABLE 29 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 72
TABLE 30 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION, 2016–2023 (USD MILLION) 73
TABLE 31 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 73
TABLE 32 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 74
TABLE 33 DEVELOPMENTS IN THE FIELD OF TDDS IN EUROPE, 2015–2018 74
TABLE 34 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 76
TABLE 35 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 76
TABLE 36 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 77
TABLE 37 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 77
TABLE 38 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 78
TABLE 39 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 78
TABLE 40 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 79
TABLE 41 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 2016–2023 (USD MILLION) 80
TABLE 42 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 80
TABLE 43 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 81
TABLE 44 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 82
TABLE 45 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 82
TABLE 46 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 83
TABLE 47 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 84
TABLE 48 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 84
TABLE 49 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 85
TABLE 50 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY COUNTRY, 2016–2023 (USD MILLION) 87
TABLE 51 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION, 2016–2023 (USD MILLION) 87
TABLE 52 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION) 88
TABLE 53 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 88
TABLE 54 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 89
TABLE 55 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 90
TABLE 56 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 90
TABLE 57 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 91
TABLE 58 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 92
TABLE 59 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 92
TABLE 60 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 93
TABLE 61 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 94
TABLE 62 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 94
TABLE 63 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION, 2016–2023 (USD MILLION) 95
TABLE 64 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 96
TABLE 65 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION) 96
TABLE 66 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 98
TABLE 67 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 2016–2023 (USD MILLION) 98
TABLE 68 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 2016–2023 (USD MILLION) 98
TABLE 69 PRODUCT LAUNCHES AND APPROVALS 102
TABLE 70 EXPANSIONS 103
TABLE 71 AGREEMENTS AND COLLABORATIONS 103